Imprimis Steps Up to Fill Need for More Affordable Drugs

By Brittany Meiling

Originally published February 18, 2016 at 1 p.m., updated February 18, 2016 at 1 p.m.

Cidara CEO Jeffrey Stein says the consequences of getting a fungal infection can be dire. Cidara’s anti-fungal drug recently received orphan drug designation from the FDA. The drug already has received fast-track status.

Cidara CEO Jeffrey Stein says the consequences of getting a fungal infection can be dire. Cidara’s anti-fungal drug recently received orphan drug designation from the FDA. The drug already has received fast-track status. Photo by Melissa Jacobs.

Local drugmaker Imprimis Pharmaceuticals is offering cheap versions of expensive Retrophin drugs to patients who need them...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129